A Phase II, Multi-center, Randomized, Placebo-controlled (Double-blind Design), Active Comparator-controlled (Open-label Design), Parallel-group, Dose-finding Study, to Evaluate the Efficacy and Safety of HEC585 Tablets in Patients With IPF
Latest Information Update: 22 Aug 2023
At a glance
- Drugs Yifenidone (Primary) ; Pirfenidone
- Indications Idiopathic pulmonary fibrosis
- Focus Therapeutic Use
- Sponsors Sunshine Lake Pharma
- 12 Apr 2023 Planned End Date changed from 11 May 2023 to 11 May 2025.
- 12 Apr 2023 Planned primary completion date changed from 10 Feb 2023 to 10 May 2024.
- 30 Sep 2021 New trial record